Document Detail

Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche.
MedLine Citation:
PMID:  15507508     Owner:  NLM     Status:  MEDLINE    
Both late menarcheal age and low calcium intake (Ca intake) during growth are risk factors for osteoporosis, probably by impairing peak bone mass. We investigated whether lasting gain in areal bone mineral density (aBMD) in response to increased Ca intake varies according to menarcheal age and, conversely, whether Ca intake could influence menarcheal age. In an initial study, 144 prepubertal girls were randomized in a double-blind controlled trial to receive either a Ca supplement (Ca-suppl.) of 850 mg/d or placebo from age 7.9-8.9 yr. Mean aBMD gain determined by dual energy x-ray absorptiometry at six sites (radius metaphysis, radius diaphysis, femoral neck, trochanter, femoral diaphysis, and L2-L4) was significantly (P = 0.004) greater in the Ca-suppl. than in the placebo group (27 vs. 21 mg/cm(2)). In 122 girls followed up, menarcheal age was recorded, and aBMD was determined at 16.4 yr of age. Menarcheal age was lower in the Ca-suppl. than in the placebo group (P = 0.048). Menarcheal age and Ca intake were negatively correlated (r = -0.35; P < 0.001), as were aBMD gains from age 7.9-16.4 yr and menarcheal age at all skeletal sites (range: r = -0.41 to r = -0.22; P < 0.001 to P = 0.016). The positive effect of Ca-suppl. on the mean aBMD gain from baseline remained significantly greater in girls below, but not in those above, the median of menarcheal age (13.0 yr). Early menarcheal age (12.1 +/- 0.5 yr): placebo, 286 +/- 36 mg/cm(2); Ca-suppl., 317 +/- 46 (P = 0.009); late menarcheal age (13.9 +/- 0.5 yr): placebo, 284 +/- 58; Ca-suppl., 276 +/- 50 (P > 0.05). The level of Ca intake during prepuberty may influence the timing of menarche, which, in turn, could influence long-term bone mass gain in response to Ca supplementation. Thus, both determinants of early menarcheal age and high Ca intake may positively interact on bone mineral mass accrual.
Thierry Chevalley; René Rizzoli; Didier Hans; Serge Ferrari; Jean-Philippe Bonjour
Related Documents :
24264078 - Volatiles from feces of wild male house mice : chemistry and effects on behavior and he...
24874518 - Non-employment histories of middle-aged men and women who died from alcohol-related cau...
22955098 - Investigation of the effectiveness of brief interventions to reduce alcohol consumption...
15507508 - Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year ...
22186298 - Characteristic analysis of peripheral blood mononuclear cell apoptosis in coke oven wor...
3693828 - Attritional lesions of the wrist joint.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2004-10-26
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  90     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-11     Completed Date:  2005-02-10     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  44-51     Citation Subset:  AIM; IM    
Service of Bone Diseases [WHO Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics, University Hospitals, CH-1211 Geneva 14, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Bone Density*
Calcium, Dietary / administration & dosage*
Double-Blind Method
Follow-Up Studies
Nutritional Physiological Phenomena
Reg. No./Substance:
0/Calcium, Dietary

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adenovirally mediated expression of insulin-like growth factors enhances the function of first trime...
Next Document:  CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity.